NPNeil D. Perkins

Neil D. Perkins

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Neil D. Perkins has a total of 34 co-authors. Here are the top co-authors by number of shared publications:

  • Sonia Rocha

    Institute of Systems, Molecular and Integrative Biology, University of Liverpool

    5 shared publications
  • Kirsteen J. Campbell

    CRUK Scotland Institute, Glasgow, UK

    4 shared publications
  • Katie Schumm

    College of Life Sciences, Division of Gene Regulation and Expression, University of Dundee, Dundee, UK

    2 shared publications
  • Lisa A. Anderson

    Division of Gene Expression and Regulation, School of Life Sciences, University of Dundee, Dundee DD1 5EH, Scotland, United Kingdom

    2 shared publications
  • Andrew W. Snowden

    Division of Gene Regulation and Expression, Department of Biochemistry, University of Dundee, Dundee DD1 5EH, Scotland, United Kingdom

    1 shared publication
  • Anthea M. Martin

    School of Life Sciences, Division of Gene Expression and Regulation, University of Dundee,1 Biomedical Research Centre, Ninewells Hospital, Dundee, Scotland, United Kingdom2

    1 shared publication

Latest Publications

  • Open Access

    Regulation of Cyclin D1 RNA Stability by SNIP1

    by Cameron P. Bracken, Steven J. Wall, Benjamin Barré, Kostya I. Panov, Paul M. Ajuh, Neil D. Perkins

    Cyclin D1 expression represents one of the key mitogen-regulated events during the G1 phase of the cell cycle, whereas Cyclin D1 overexpression is frequently associated with human malignancy. Here, we describe a novel mechanism regulating Cyclin D1 levels. We find that SNIP1, previously identified as a regulator of Cyclin D1 expression, does not, as previously thought, primarily function as a transcriptional coactivator for this gene. Rather, SNIP1 plays a critical role in cotranscriptional or posttranscriptional Cyclin D1 mRNA stability. Moreover, we show that the majority of nucleoplasmic SNIP1 is present within a previously undescribed complex containing SkIP, THRAP3, BCLAF1, and Pinin, all proteins with reported roles in RNA processing and transcriptional regulation. We find that this complex, which we have termed the SNIP1/SkIP–associated RNA-processing complex, is coordinately recruited to both the 3′ end of the Cyclin D1 gene and Cyclin D1 RNA. Significantly, SNIP1 is required for the further recruitment of the RNA processing factor U2AF65 to both the Cyclin D1 gene and RNA. This study shows a novel mechanism regulating Cyclin D1 expression and offers new insight into the role of SNIP1 and associated proteins as regulators of proliferation and cancer. [Cancer Res 2008;68(18):7621–8]


  • Retracted
    Open Access

    Retracted: A cell cycle regulatory network controlling NF‐κB subunit activity and function

    by Benjamin Barré, Neil D Perkins

    EMBO Press is an editorially independent publishing platform for the development of EMBO scientific publications.


  • Regulation of ATR-dependent pathways by the FHA domain containing protein SNIP1

    by K C Roche, S Rocha, C P Bracken, N D Perkins

    The forkhead associated (FHA) domain-containing protein Smad nuclear interacting protein 1 (SNIP1) has multiple cellular functions, including the ability to interact with DNA-binding transcription factors and transcriptional coactivators. Moreover, we have demonstrated previously that SNIP1 regulates cyclin D1 expression and promoter activity. Here, we identify a new function for SNIP1 as a regulator of ATR checkpoint kinase-dependent pathways in human U-2 OS osteosarcoma cells: SNIP1 is required for p53 induction in response to ultraviolet light treatment and selectively regulates the phosphorylation of known ATR target proteins, including p53, Chk1 and the histone variant H2AX. These activities are independent of its ability to regulate cyclin D1 expression. Significantly, SNIP1 is also required for ATR-dependent functions of the human p14ARF tumour suppressor, including its ability to modulate the activity of the RelA(p65) NF-B subunit. This, together with its other described functions, suggests that SNIP1 could have an important role during tumorigenesis and cancer therapy.


  • Open Access

    Transcriptional profiling of the LPS induced NF-κB response in macrophages

    by Omar Sharif, Viacheslav N Bolshakov, Stephanie Raines, Peter Newham, Neil D Perkins

    Background: Exposure of macrophages to bacterial products such as lipopolysaccharide (LPS) results in activation of the NF-κB transcription factor, which orchestrates a gene expression programme that underpins the macrophage-dependent immune response. These changes include the induction or repression of a wide range of genes that regulate inflammation, cell proliferation, migration and cell survival. This process is tightly regulated and loss of control is associated with conditions such as septic shock, inflammatory diseases and cancer. To study this response, it is important to have in vitro model systems that reflect the behaviour of cells in vivo. In addition, it is necessary to understand the natural differences that can occur between individuals. In this report, we have investigated and compared the LPS response in macrophage derived cell lines and peripheral blood mononuclear cell (PBMC) derived macrophages. Results: Gene expression profiles were determined following LPS treatment of THP-1 cells for 1 and 4 hours. LPS significantly induced or repressed 72 out of 465 genes selected as being known or putative NF-κB target genes, which exhibited 4 temporal patterns of expression. Results for 34 of these genes, including several genes not previously identified as LPS target genes, were validated using real time PCR. A high correlation between microarray and real time PCR data was found. Significantly, the LPS induced expression profile of THP-1 cells, as determined using real time PCR, was found to be very similar to that of human PBMC derived macrophages. Interestingly, some differences were observed in the LPS response between the two donor PBMC macrophage populations. Surprisingly, we found that the LPS response in U937 cells was dramatically different to both THP-1 and PBMC derived macrophages. Conclusion: This study revealed a dynamic and diverse transcriptional response to LPS in macrophages, involving both the induction and repression of gene expression in a time dependent manner. Moreover, we demonstrated that the LPS induced transcriptional response in the THP-1 cell line is very similar to primary PBMC derived macrophages. Therefore, THP-1 cells represent a good model system for studying the mechanisms of LPS and NF-κB dependent gene expression.


  • Top Cited Papers

    Integrating cell-signalling pathways with NF-κB and IKK function

    by Neil D. Perkins

    The nuclear factor (NF)-κB, inhibitor of NF-κB (IκB) and IκB kinase (IKK) pathway is activated in response to various stimuli in many cell types. NF-κB is activated by many mechanisms, including the canonical pathway, which activates the IKK complex and results in the degradation of IκB in response to inflammatory stimuli. Several NF-κB- and IκB-independent substrates for the IKK proteins are now being identified. These indicate that in addition to induction of NF-κB, these kinases might function to programme the overall cellular response to specific activating stimuli. The consequences of NF-κB activation can vary depending on the context in which activation occurs. This modulation is at least in part due to the regulation of NF-κB subunits in the nucleus, where they translocate after release from cytoplasmic IκB proteins. One mechanism of regulating NF-κB subunit function is through post-translational modifications such as phosphorylation and acetylation. This allows other cell-signalling proteins to influence NF-κB function and therefore serves as a mechanism to integrate their activities with the NF-κB and IKK pathway. NF-κB subunits can also bind DNA cooperatively and activate transcription synergistically with heterologous transcription factors. As independent cell-signalling pathways regulate many of these factors, this provides another mechanism through which NF-κB and IKK activity can be integrated with the overall cellular response to multiple stimuli. Feedback loops exist in which the activation of NF-κB target genes can influence the later time points of the NF-κB response to specific cell stimuli. Crosstalk with the Jun N-terminal kinase (JNK), p53 and nuclear-receptor pathways provide specific examples of the diversity of mechanisms that exist to link NF-κB function to other important networks that regulate cell fate, the immune response and inflammation. The complexity of the mechanisms regulating NF-κB function presents both a challenge and an opportunity when seeking to exploit NF-κB function in a clinical setting. Results indicate that care must be taken when using NF-κB or IKK inhibitors in the clinic, but they also indicate that understanding these pathways will improve diagnostic capabilities and maximize the effectiveness of such inhibitors.


  • Post-translational modifications regulating the activity and function of the nuclear factor kappa B pathway

    by N D Perkins

    The diverse cellular and biological functions of the nuclear factor kappa B (NF-B) pathway, together with the catastrophic consequences of its aberrant regulation, demand specific and highly regulated control of its activity. As described in this review, regulation of the NF-B pathway is brought about through multiple post-translational modifications that control the activity of the core components of NF-B signaling: the IB kinase (IKK) complex, the IB proteins and the NF-B subunits themselves. These regulatory modifications, which include phosphorylation, ubiquitination, acetylation, sumoylation and nitrosylation, can vary, depending on the nature of the NF-B-inducing stimulus. Moreover, they frequently have distinct, sometimes antagonistic, functional consequences and the same modification can have different effects depending on the context. Given the important role of NF-B in human health and disease, understanding these pathways will not only provide valuable insights into mechanism and function, but could also lead to new drug targets and the development of diagnostic and prognostic biomarkers for many pathological conditions.


  • Open Access

    Regulation of p53 tumour suppressor target gene expression by the p52 NF‐κB subunit

    by Katie Schumm, Sonia Rocha, Jorge Caamano, Neil D Perkins

    The p52/p100 nuclear factor kappa B (NF‐κB) subunit (NF‐κB2) is aberrantly expressed in many tumour types and has been implicated as a regulator of cell proliferation. Here, we demonstrate that endogenous p52 is a direct regulator of Cyclin D1 expression. However, stimulation of Cyclin D1 expression alone cannot account for all the cell cycle effects of p52/p100 and we also find that p52 represses expression of the Cyclin‐dependent kinase inhibitor p21WAF/CIP1. Significantly, this latter effect is dependent upon basal levels of the tumour suppressor p53. By contrast, p52 cooperates with p53 to regulate other known p53 target genes such as PUMA, DR5, Gadd45α and Chk1. p52 associates directly with these p53‐regulated promoters where it regulates coactivator and corepressor binding. Moreover, recruitment of p52 is p53 dependent and does not require p52‐DNA‐binding activity. These results reveal a complex role for p52 as regulator of cell proliferation and p53 transcriptional activity. Furthermore, they imply that in some cell types, p52 can regulate p53 function and influence p53‐regulated decision‐making following DNA damage and oncogene activation.


  • Open Access

    Differential regulation of NF-κB activation and function by topoisomerase II inhibitors

    by Kirsteen J Campbell, John M O'SHea, Neil D Perkins

    Background: While many common chemotherapeutic drugs and other inducers of DNA-damage result in both NF-κB nuclear translocation and DNA-binding, we have previously observed that, depending on the precise stimulus, there is great diversity of the function of NF-κB. In particular, we found that treatment of U-2 OS osteosarcoma cells with the anthracycine daunorubicin or with ultraviolet (UV-C) light resulted in a form of NF-κB that repressed rather than induced NF-κB reporter plasmids and the expression of specific anti-apoptotic genes. Anthracyclines such as daunorubicin can induce DNA-damage though inhibiting topoisomerase II, intercalating with DNA and undergoing redox cycling to produce oxygen free radicals. In this study we have investigated other anthracyclines, doxorubicin and aclarubicin, as well as the anthracenedione mitoxantrone together with the topoisomerase II inhibitor ICRF-193, which all possess differing characteristics, to determine which of these features is specifically required to induce both NF-κB DNA-binding and transcriptional repression in U-2 OS cells. Results: The use of mitoxantrone, which does not undergo redox cycling, and the reducing agent epigallocatechingallate (EGCG) demonstrated that oxygen free radical production is not required for induction of NF-κB DNA-binding and transcriptional repression by these agents and UV-C. In addition, the use of aclarubicin, which does not directly inhibit topoisomerase II and ICRF-193, which inhibits topoisomerase II but does not intercalate into DNA, demonstrated that topoisomerase II inhibition is not sufficient to induce the repressor form of NF-κB. Conclusion: Induction of NF-κB DNA-binding and transcriptional repression by topoisomerase II inhibitors was found to correlate with an ability to intercalate into DNA. Although data from our and other laboratories indicates that topoisomerase II inhibition and oxygen free radicals do regulate NF-κB, they are not required for the particular ability of NF-κB to repress rather than activate transcription. Together with our previous data, these results demonstrate that the nature of the NF-κB response is context dependent. In a clinical setting such effects could profoundly influence the response to chemotherapy and suggest that new methods of analyzing NF-κB function could have both diagnostic and prognostic value.


  • Open Access

    Good cop, bad cop: the different faces of NF-κB

    by N D Perkins, T D Gilmore

    Complexes formed from the nuclear factor κB (NF-κB) family of transcription factors are ubiquitously expressed and are induced by a diverse array of stimuli. This results in their becoming activated in a wide variety of different settings. While the functions of NF-κB in many of these contexts have been the subject of intense research and are now well established, it is also clear that there is great diversity in the effects and consequences of NF-κB activation. NF-κB subunits do not necessarily regulate the same genes, in an identical manner, in all of the different circumstances in which they are induced. This review will discuss the different functions of NF-κB, the pathways that modulate NF-κB subunit activity and, in contrast to its more commonly thought of role as a promoter of cancer cell growth and survival, the ability of NF-κB, under some circumstances, to behave as a tumor suppressor.


  • Open Access

    Regulation of NF‐κB and p53 through activation of ATR and Chk1 by the ARF tumour suppressor

    by Sonia Rocha, Michelle D Garrett, Kirsteen J Campbell, Katie Schumm, Neil D Perkins

    The ARF tumour suppressor is a central component of the cellular defence against oncogene activation. In addition to activating p53 through binding Mdm2, ARF possesses other functions, including an ability to repress the transcriptional activity of the antiapoptotic RelA(p65) NF‐κB subunit. Here we demonstrate that ARF induces the ATR‐ and Chk1‐dependent phosphorylation of the RelA transactivation domain at threonine 505, a site required for ARF‐dependent repression of RelA transcriptional activity. Consistent with this effect, ATR and Chk1 are required for ARF‐induced sensitivity to tumour necrosis factor α‐induced cell death. Significantly, ATR activity is also required for ARF‐induced p53 activity and inhibition of proliferation. ARF achieves these effects by activating ATR and Chk1. Furthermore, ATR and its scaffold protein BRCA1, but not Chk1, relocalise to specific nucleolar sites. These results reveal novel functions for ARF, ATR and Chk1 together with a new pathway regulating RelA NF‐κB function. Moreover, this pathway provides a mechanism through which ARF can remodel the cellular response to an oncogenic challenge and execute its function as a tumour suppressor.